På dansk – in English below
Pressemeddelse Cytovac Jan. 14, 2020 Cytovac har igangsat en ny privat kapital rejsning i perioden d. 14-31 Januar, hvor selskabet ønsker at rejse 15 millioner danske kroner (SEK 21.5 millioner), der skal finansiere selskabets aktiviteter indtil udgangen af 2020. Cytovac har besluttet at starte et investigator-initieret studie i triple negativ brystkræft (CV007) i samarbejde med Odense Universitets Hospital. Studiet forventes påbegyndt senere i 2020. Til dette studie vil CytoVacs 2nd generations Alecsat produkt blive benyttet. CytoVac følger hermed sin tidligere oplyste kliniske udviklingsplan. Cytovac har afsluttet CV006 fase 2 studiet i patienter med hjernekræft (glioblastom) i Sverige. Studiet inkluderede 62 patienter randomiseret 1:2 til at modtage standard behandling eller standard behandling plus ALECSAT behandling. Det primære formål med studiet var at undersøge effekten af ALECSAT på udvikling af glioblastom. Fase 2 studiet viste ingen statistisk signifikant effekt af ALECSAT behandlingen på udviklingen af glioblastom. CytoVacs CV003 fase 1 studie (25 patienter med glioblastom) demonstrerede ellers 2 patienter med komplet respons og en patientmed delvis respons. Selskabets direktør, Kim Arvid Nielsen, har besluttet ikke at være en del af den fremtidige udvikling hos CytoVac, men har valgt at stå til rådighed for selskabet i en fremadrettet periode. Selskabets finanschef, Lone Dahl Andersen, bliver konstitueret som ny direktør for selskabet foreløbigt frem til 1. marts 2020. Bestyrelsen
In English
Press release Cytovac January 14, 2020 Cytovac has initiated a new private capital raise for the period January 14-31, 2020, Cytovac wishes to raise DKK 15 million (SEK 21.5 million), which will finance the company´s activities until the end of 2020. Cytovac has decided to start the investigator-initiated study in triple negative breast cancer (CV007) in collaboration with Odense University hospital. The study is expected to start later in 2020. For this study Cytovac´s 2nd generation ALECSAT product will be used. Thus, Cytovac continues its previously announced clinical development plan. Cytovac has completed the CV006 phase 2 study in patients with brain cancer (glioblastoma) in Sweden. The study included 62 patients randomized 1:2 to receive standard treatment or standard treatment plus ALECSAT therapy. The primary objective of the study was to investigate the effect of ALECSAT on glioblastoma progression. The phase 2 study showed no statistically significant effect of ALECSAT therapy on the progression of glioblastoma. Cytovac´s CV003 phase 1 study (25 patients with advanced glioblastoma) otherwise demonstrated 2 patients with complete response and one patient with partial response. The company´s CEO Kim Arvid Nielsen has decided not to be a part of the future development at Cytovac but has chosen to be available to the company for a future period. The company´s CFO, Lone Dahl Andersen will be appointed as new CEO of the company provisionally until March 1, 2020. Board of Directors